A New Immunologic Method for Detection of Occult Breast Cancer.
Annual rept. 1 Oct 94-30 Sep 95,
JOHN WAYNE INST FOR CANCER TREATMENT AND RESEARCH SANTA MONICA CA
Pagination or Media Count:
We investigated the incidence of a 90kD subunit containing glycoprotein tumor-associated antigen TAA- specific immune complexes IC in sera of breast cancer patients and correlated it with other tumor markers - CEA and CAi5-3. Sera were obtained from 106 patients with histopathologically proven breast cancer, and from 107 self-proclaimed healthy females. Serum samples were analyzed for the presence of the 90kD glycoprotein TAA-specific IC by a murine monoclonal antibody, ADl-40F4, based ELISA. The antibody, developed against an autoimmunogenic glycoprotein TAA, recognized an epitope that is different from those recognized by human polyclonal antibodies. IC captured by AD1-40F4 were realized by enzyme conjugated goat anti-human IgG. A positive test corresponded to a normalized ELISA value above 0.410 OD mean plus 3 SD at 405nm. The incidence of 90kD glycoprotein TAA-specific IC was significantly higher p0.05 in breast cancer patients 63, or 67106 than in healthy controls 2.8, or 3107. Comparison of the glycoprotein TAA-specific IC results in breast cancer patients with evidence of disease with results of CEA and CA 15-3 revealed that the incidence of abnormal values was increased to 91. Thus, use of the glycoprotein TAA-specific IC marker in conjunction with CEA andor CA15-3 may prove to be more sensitive than when used alone for immunodiagnosis and immunoprognosis.
- Medicine and Medical Research
- Anatomy and Physiology